Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)

Eton Pharmaceuticals has disclosed Cost of Revenue across 7 years of filings, most recently posting $8.2 million for Q4 2025.

• Cost of Revenue for Q4 2025 came in at $8.2 million, up 58.21% year-over-year; the trailing twelve-month figure through Dec 2025 was $30.5 million (up 95.28% YoY), and the FY2025 annual result was $37.2 million, up 138.53% from the prior year.
• Cost of Revenue came in at $8.2 million for Q4 2025 at Eton Pharmaceuticals, down from $14.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.6 million in Q3 2025 to a low of $174000.0 in Q2 2021.
• The 5-year median for Cost of Revenue is $2.5 million (2023), against an average of $3.3 million.
• Across the five-year window, Cost of Revenue jumped 1477.59% in 2022 and sank 77.19% in 2025, its largest moves.
• Eton Pharmaceuticals' Cost of Revenue stood at $372000.0 in 2021, then soared by 474.73% to $2.1 million in 2022, then jumped by 72.26% to $3.7 million in 2023, then jumped by 40.4% to $5.2 million in 2024, then soared by 58.21% to $8.2 million in 2025.
• The last three Cost of Revenue figures came in at $8.2 million (Q4 2025), $14.6 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.